NCT06314880View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

PHASE1RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 22, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)

Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

BIOLOGICAL

Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)

Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

BIOLOGICAL

Placebo control

Placebo control. 20 people/group.

Trial Locations (1)

530028

RECRUITING

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning

All Listed Sponsors
lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY